Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance
Countries citing papers authored by Norman E. Lepor
Since
Specialization
Citations
This map shows the geographic impact of Norman E. Lepor's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Norman E. Lepor with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Norman E. Lepor more than expected).
This network shows the impact of papers produced by Norman E. Lepor. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Norman E. Lepor. The network helps show where Norman E. Lepor may publish in the future.
Co-authorship network of co-authors of Norman E. Lepor
This figure shows the co-authorship network connecting the top 25 collaborators of Norman E. Lepor.
A scholar is included among the top collaborators of Norman E. Lepor based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Norman E. Lepor. Norman E. Lepor is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Gottlieb, Roberta A., et al.. (2008). Chemotherapy and cardiotoxicity.. PubMed. 9(2). 75–83.57 indexed citations
12.
Lepor, Norman E.. (2007). Key Findings From the 2006 World Congress of Cardiology. Reviews in Cardiovascular Medicine. 8(2). 90–100.1 indexed citations
13.
Lepor, Norman E.. (2007). Key Findings From the 2007 European Society of Cardiology Congress. Reviews in Cardiovascular Medicine. 8(4). 220–227.1 indexed citations
14.
Wiviott, Stephen D., Alan D. Michelson, Peter B. Berger, Norman E. Lepor, & Dean J. Kereiakes. (2006). Therapeutic goals for effective platelet inhibition: a consensus document.. PubMed. 7(4). 214–25.5 indexed citations
15.
Jacobs, Alice K., Norman E. Lepor, & Alan C. Yeung. (2004). Best of TCT 2004. Reviews in Cardiovascular Medicine. 5(4). 216–222.2 indexed citations
16.
Lepor, Norman E.. (2003). A Review of PharmacologicInterventions to PreventContrast-Induced Nephropathy. Reviews in Cardiovascular Medicine. 4. 34–42.2 indexed citations
17.
Creager, Mark A., David P. Faxon, Gregg C. Fonarow, et al.. (2002). Best of the ACC Scientific Session 2002. Reviews in Cardiovascular Medicine. 3(2). 85–104.2 indexed citations
18.
Lepor, Norman E.. (2001). Radiocontrast Nephropathy: Managing the High-Risk Patient. Reviews in Cardiovascular Medicine. 2. 1–3.1 indexed citations
19.
Lepor, Norman E.. (2001). Highlights from the American College of Cardiology 32nd Annual Cardiovascular Conference January 15-19, 2001, Snowmass, CO. Reviews in Cardiovascular Medicine. 2(4). 206–208.1 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.